SCHEMBL2072640

SCHEMBL2072640

CNCCC(c1cc(F)cnc1Cl)c1c[nH]c2cccc(OC)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 4/20 0.39
CYP2D6 P10635 2/20 0.39
SLC6A2 P23975 2/20 0.39
KCNH2 Q12809 1/20 0.39
HTR6 P50406 4/20 0.38
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
HTR2A P28223 1/20 0.35
MMP9 P14780 1/20 0.35
HTR1A P08908 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HPGD P15428 1/20 0.34
HTR7 P34969 1/20 0.34
HTR2B P41595 1/20 0.34
HTR5A P47898 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2073923 0.84 SLC6A4 (0.41) SLC6A4CYP2D6SLC6A2KCNH2HTR6
SCHEMBL2072912 0.80 SLC6A4 (0.54) SLC6A4CYP2D6SLC6A2KCNH2HTR6
SCHEMBL2074364 0.79 SLC6A4 (0.47) SLC6A4CYP2D6SLC6A2KCNH2HTR6
SCHEMBL2071453 0.79 SLC6A2 (0.43) SLC6A4CYP2D6SLC6A2KCNH2HTR6
SCHEMBL2074117 0.78 SLC6A4 (0.43) SLC6A4CYP2D6SLC6A2KCNH2HTR6
SCHEMBL2074258 0.77 SLC6A4 (0.41) SLC6A4CYP2D6SLC6A2KCNH2HTR6
SCHEMBL2074216 0.77 SLC6A4 (0.46) SLC6A4CYP2D6SLC6A2KCNH2HTR6
SCHEMBL2074088 0.77 SLC6A2 (0.43) SLC6A4CYP2D6SLC6A2KCNH2HTR6
SCHEMBL2073643 0.77 SLC6A4 (0.64) SLC6A4CYP2D6SLC6A2KCNH2HTR6
SCHEMBL1714535 0.77 SLC6A4 (0.64) SLC6A4CYP2D6SLC6A2KCNH2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863305-B2 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC (US) 2011-01-04 US disclosed
US-7863305-B2 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC (US) 2011-01-04 US disclosed
US-7863305-B2 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC (US) 2011-01-04 US disclosed
EP-1756054-B1 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR HOFFMANN LA ROCHE (CH) 2010-03-31 EP disclosed
US-20060025467-A1 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025467-A1 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors TPH1, HTR1A, HTR3A SLC6A4 14/4885CYP2D6 67/4885SLC6A2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.